Jane C. Moore

4.4k total citations · 1 hit paper
57 papers, 3.1k citations indexed

About

Jane C. Moore is a scholar working on Hematology, Surgery and Immunology. According to data from OpenAlex, Jane C. Moore has authored 57 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Hematology, 26 papers in Surgery and 14 papers in Immunology. Recurrent topics in Jane C. Moore's work include Platelet Disorders and Treatments (40 papers), Heparin-Induced Thrombocytopenia and Thrombosis (24 papers) and Complement system in diseases (12 papers). Jane C. Moore is often cited by papers focused on Platelet Disorders and Treatments (40 papers), Heparin-Induced Thrombocytopenia and Thrombosis (24 papers) and Complement system in diseases (12 papers). Jane C. Moore collaborates with scholars based in Canada, United States and Australia. Jane C. Moore's co-authors include Theodore E. Warkentin, John G. Kelton, Jo‐Ann I. Sheppard, Peter Horsewood, Christopher Sigouin, Catherine P.M. Hayward, Richard J. Cook, Donald M. Arnold, Kathleen N. Moore and Libero Ajello and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Journal of the American College of Cardiology.

In The Last Decade

Jane C. Moore

56 papers receiving 3.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of the patient population on the risk for heparin-induced thrombocytopenia

2000 646 citations Theodore E. Warkentin, Jo‐Ann I. Sheppard et al. profile →

Peers

Countries citing papers authored by Jane C. Moore

Since Specialization

Citations

This map shows the geographic impact of Jane C. Moore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane C. Moore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane C. Moore more than expected).

Fields of papers citing papers by Jane C. Moore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane C. Moore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane C. Moore. The network helps show where Jane C. Moore may publish in the future.

Co-authorship network of co-authors of Jane C. Moore

This figure shows the co-authorship network connecting the top 25 collaborators of Jane C. Moore. A scholar is included among the top collaborators of Jane C. Moore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jane C. Moore. Jane C. Moore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Investigation of anti-PF4 versus anti-PF4/heparin reactivity using fluid-phase enzyme immunoassay for 4 anti-PF4 disorders: classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, vaccine-induced immune thrombotic thrombocytopenia, and spontaneous HIT 2023 ·Journal of Thrombosis and Haemostasis ·Theodore E. Warkentin, Donald M. Arnold, Jo‐Ann I. Sheppard, Jane C. Moore, John G. Kelton, Ishac Nazy	18
2	Platelet‐activating immune complexes identified in critically ill COVID‐19 patients suspected of heparin‐induced thrombocytopenia 2021 ·Journal of Thrombosis and Haemostasis ·Ishac Nazy, Stefan D. Jevtic, Jane C. Moore, Angela Huynh, James W. Smith, John G. Kelton, Donald M. Arnold	63
3	Combination of two complementary automated rapid assays for diagnosis of heparin‐induced thrombocytopenia (HIT) 2020 ·Journal of Thrombosis and Haemostasis ·Theodore E. Warkentin, Jo‐Ann I. Sheppard, James W. Smith, Na Li, Jane C. Moore, Donald M. Arnold, Ishac Nazy	24
4	Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia 2018 ·Journal of Thrombosis and Haemostasis ·Ishac Nazy, Rumi Clare, Phillip Staibano, Theodore E. Warkentin, Mark Larché, Jane C. Moore, James W. Smith, Richard Whitlock, John G. Kelton, Donald M. Arnold	6
5	Effect of Buttonhole Cannulation With a Polycarbonate Peg on In-Center Hemodialysis Fistula Outcomes: A Randomized Controlled Trial 2013 ·American Journal of Kidney Diseases ·Emma Vaux, Jennie King, (unknown), Jane C. Moore, (unknown), Isabel Reading, Ramesh Naik	66
6	Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura 2012 ·Transfusion ·Vinai Bhagirath, John G. Kelton, Jane C. Moore, Donald M. Arnold	14
7	Congenital thrombotic thrombocytopenic purpura (cTTP) with two novel mutations 2012 ·Pediatric Blood & Cancer ·(unknown), Erica Rurali, Louis D. Wadsworth, John K. Wu, Jane C. Moore, Elena Bresin	5
8	Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex 2007 ·Kidney International ·Marc Carrier, Marc Rodger, Dean Fergusson, (unknown), M.J. Kovacs, Jane C. Moore, John G. Kelton, Greg Knoll	29
9	Intravenous immunoglobulin as an adjunct to plasma exchange for the treatment of chronic thrombotic thrombocytopenic purpura 2007 ·Vox Sanguinis ·Jane C. Moore, Donald M. Arnold, Brian Leber, Rumi Clare, (unknown), John G. Kelton	8
10	Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: A survey of North American specialized coagulation laboratories 2007 ·Thrombosis and Haemostasis ·Catherine P.M. Hayward, Karen A. Moffat, Jane C. Moore, Theodore E. Warkentin, James L. Zehnder, Elizabeth Price	49
11	The prevalence of antibodies to the platelet factor 4 -heparin complex and association with access thrombosis in patients on chronic hemodialysis 2006 ·Thrombosis Research ·Marc Carrier, Greg Knoll, Michael J. Kovacs, Jane C. Moore, Dean Fergusson, Marc Rodger	27
12	Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: How much class do we need? 2005 ·Journal of Laboratory and Clinical Medicine ·Theodore E. Warkentin, Jo‐Ann I. Sheppard, Jane C. Moore, Kathleen N. Moore, Christopher Sigouin, John G. Kelton	192
13	Dissociation between the level of von Willebrand factor‐cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura 2004 ·American Journal of Hematology ·Carolyn Snider, Jane C. Moore, Theodore E. Warkentin, (unknown), Catherine P.M. Hayward, John G. Kelton	16
14	Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome 2003 ·Transfusion Medicine Reviews ·Theodore E. Warkentin, Jane C. Moore, Sonia S. Anand, Eva Lonn, David Morgan	142
15	The IgG subclasses of platelet‐associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura 2003 ·British Journal of Haematology ·Howard H.W. Chan, Jane C. Moore, (unknown), Theodore E. Warkentin, John G. Kelton	58
16	A prospective study of protein‐specific assays used to investigate idiopathic thrombocytopenic purpura 1999 ·British Journal of Haematology ·Margaret Warner, Jane C. Moore, Theodore E. Warkentin, Aurelio Santos, John G. Kelton	126
17	Serum-induced platelet procoagulant activity: An assay for the characterization of prothrombotic disorders 1999 ·Journal of Laboratory and Clinical Medicine ·Margaret Warner, (unknown), Jane C. Moore, Theodore E. Warkentin, Catherine P.M. Hayward, J. G. Kelton	20
18	Factor V Is Complexed with Multimerin in Resting Platelet Lysates and Colocalizes with Multimerin in Platelet α-Granules 1995 ·Journal of Biological Chemistry ·Catherine P.M. Hayward, Emilia Furmaniak-Kazmierczak, Anne-Marie Cieutat, Jane C. Moore, D F Bainton, Michael E. Nesheim, John G. Kelton, Graham P. Côté	48
19	Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura 1990 ·British Journal of Haematology ·Jane C. Moore, William G. Murphy, J. G. Kelton	52
20	Relationship between platelet aggregating factor and von Willebrand factor in thrombotic thrombocytopenic purpura 1987 ·British Journal of Haematology ·William G. Murphy, Jane C. Moore, Ronald D. Barr, Mohan Pai, John G. Kelton	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact